Tags

Type your tag names separated by a space and hit enter

Thrombin-activatable fibrinolysis inhibitor (TAFI) levels and its polymorphism rs3742264 are associated with dyslipidemia in a cohort of Brazilian subjects.
Clin Chim Acta 2014; 433:76-83CC

Abstract

BACKGROUND

Dyslipidemia, a metabolic alteration that affects lipoprotein levels, is considered a major risk factor for atherosclerosis and its complications. Dyslipidemia also affects the hemostatic system, especially impairing fibrinolysis, and increased levels of thrombin-activatable fibrinolysis inhibitor (TAFI) have been associated with cardiovascular events.

OBJECTIVES AND METHODS

This study evaluated the association of acquired risk factors (hypertension, body mass index - BMI, smoking, sedentary lifestyle, use or not of oral contraceptives and hormone replacement therapy, and post-menopause status), the polymorphisms Thr325Ile (rs1926447), Ala147Thr (rs3742264) and +1542C/G (rs940) in the TAFI gene, and TAFI plasma levels in 109 dyslipidemic and 105 normolipemic individuals. Biochemical analyses and TAFI levels were evaluated by colorimetric/turbidimetric assays and ELISA, respectively. Genotypic and allelic frequencies were determined by polymerase chain reaction (PCR).

RESULTS

Hypertension, increased BMI, and menopause were more common in dyslipidemic individuals, who had higher TAFI levels. The alleles 325Ile, Ala147, and C showed association with lower TAFI levels. The rs3742264 polymorphism was associated with dyslipidemia in males.

CONCLUSIONS

The results suggest that TAFI levels are independently associated to dyslipidemia and that the polymorphism rs3742264 may be related to cardiovascular risk in male subjects.

Authors+Show Affiliations

Departamento de Biologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.Colégio Técnico, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.Departamento de Biologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. Electronic address: karinabgb@gmail.com.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24631134

Citation

Santos, Izabela R., et al. "Thrombin-activatable Fibrinolysis Inhibitor (TAFI) Levels and Its Polymorphism Rs3742264 Are Associated With Dyslipidemia in a Cohort of Brazilian Subjects." Clinica Chimica Acta; International Journal of Clinical Chemistry, vol. 433, 2014, pp. 76-83.
Santos IR, Fernandes AP, Carvalho MG, et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) levels and its polymorphism rs3742264 are associated with dyslipidemia in a cohort of Brazilian subjects. Clin Chim Acta. 2014;433:76-83.
Santos, I. R., Fernandes, A. P., Carvalho, M. G., Sousa, M. O., Ferreira, C. N., & Gomes, K. B. (2014). Thrombin-activatable fibrinolysis inhibitor (TAFI) levels and its polymorphism rs3742264 are associated with dyslipidemia in a cohort of Brazilian subjects. Clinica Chimica Acta; International Journal of Clinical Chemistry, 433, pp. 76-83. doi:10.1016/j.cca.2014.02.030.
Santos IR, et al. Thrombin-activatable Fibrinolysis Inhibitor (TAFI) Levels and Its Polymorphism Rs3742264 Are Associated With Dyslipidemia in a Cohort of Brazilian Subjects. Clin Chim Acta. 2014 Jun 10;433:76-83. PubMed PMID: 24631134.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Thrombin-activatable fibrinolysis inhibitor (TAFI) levels and its polymorphism rs3742264 are associated with dyslipidemia in a cohort of Brazilian subjects. AU - Santos,Izabela R, AU - Fernandes,Ana P, AU - Carvalho,Maria G, AU - Sousa,Marinez O, AU - Ferreira,Cláudia N, AU - Gomes,Karina B, Y1 - 2014/03/11/ PY - 2013/12/03/received PY - 2014/02/20/revised PY - 2014/02/28/accepted PY - 2014/3/18/entrez PY - 2014/3/19/pubmed PY - 2015/1/16/medline KW - Dyslipidemia KW - Fibrinolysis KW - Polymorphisms KW - Risk factor KW - TAFI SP - 76 EP - 83 JF - Clinica chimica acta; international journal of clinical chemistry JO - Clin. Chim. Acta VL - 433 N2 - BACKGROUND: Dyslipidemia, a metabolic alteration that affects lipoprotein levels, is considered a major risk factor for atherosclerosis and its complications. Dyslipidemia also affects the hemostatic system, especially impairing fibrinolysis, and increased levels of thrombin-activatable fibrinolysis inhibitor (TAFI) have been associated with cardiovascular events. OBJECTIVES AND METHODS: This study evaluated the association of acquired risk factors (hypertension, body mass index - BMI, smoking, sedentary lifestyle, use or not of oral contraceptives and hormone replacement therapy, and post-menopause status), the polymorphisms Thr325Ile (rs1926447), Ala147Thr (rs3742264) and +1542C/G (rs940) in the TAFI gene, and TAFI plasma levels in 109 dyslipidemic and 105 normolipemic individuals. Biochemical analyses and TAFI levels were evaluated by colorimetric/turbidimetric assays and ELISA, respectively. Genotypic and allelic frequencies were determined by polymerase chain reaction (PCR). RESULTS: Hypertension, increased BMI, and menopause were more common in dyslipidemic individuals, who had higher TAFI levels. The alleles 325Ile, Ala147, and C showed association with lower TAFI levels. The rs3742264 polymorphism was associated with dyslipidemia in males. CONCLUSIONS: The results suggest that TAFI levels are independently associated to dyslipidemia and that the polymorphism rs3742264 may be related to cardiovascular risk in male subjects. SN - 1873-3492 UR - https://www.unboundmedicine.com/medline/citation/24631134/Thrombin_activatable_fibrinolysis_inhibitor__TAFI__levels_and_its_polymorphism_rs3742264_are_associated_with_dyslipidemia_in_a_cohort_of_Brazilian_subjects_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0009-8981(14)00106-5 DB - PRIME DP - Unbound Medicine ER -